pharmaphorum
JANUARY 29, 2021
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Zinc fingers.
Pharmaceutical Technology
FEBRUARY 13, 2023
This is particularly the case for pediatric forms of epilepsy where gene editing techniques like Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are becoming more important, says Ferraro. In his work, Ferraro focuses on the links between gene variations and different responses to drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MAY 29, 2024
Closed Loop Medicine and Pharmanovia TechBio Closed Loop Medicine and pharma company have initiated the OptiZest study and recruited the first patient. ERS Genomics and IRBM ERS Genomics and IRBM have signed an agreement granting IRBM access to ERS’ CRISPR/Cas9 patent portfolio.
Drug Discovery World
MAY 6, 2024
As companies move through the phases of development, they benefit from a long-established ecosystem of competency in clinical regulation. So, in this way there is a cross fertilisation from the bigger companies to newer ones. More than 400 companies now make up Lithuania’s life sciences sector 4.
XTalks
DECEMBER 20, 2023
In 2024, pharma companies and emerging biotechs will improve candidate safety profiles and reduce off-target effects by exploiting predictive intelligence unlocked by AI,” she predicts. CRISPR Gene Editing Therapeutics CRISPR/Cas-9 technology makes lists like this almost every year, and for good reason.
Drug Discovery World
JANUARY 26, 2023
As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% in 2022, a steep decline compared to the record 6.8% the industry experienced in 2021.
Drug Discovery World
OCTOBER 16, 2023
Despite the overall reduction in major pharma R&D centres in the UK, global pharma companies continue to engage with academic and biotech organisations here, particularly in hotspots such as the Golden Triangle, the Northwest, and Scotland, through the strong networks that have been developed between these organisations.
Expert insights. Personalized for you.
145 
Let's personalize your content